Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0738-081x(02)00367-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Anaphylactic and Anti-allergenic Properties of Shuanghuanglian: A Review.
Comb Chem High Throughput Screen
January 2025
Baoying People's Hospital, Yangzhou 225800, China.
Shuanghuanglian (SHL) and its primary constituents have demonstrated protective effects against allergenic diseases. This review examines the anaphylactic and anti-allergenic activities of SHL and its constituents. We also discuss potential avenues for future research, particularly regarding the expansion of the clinical applications of SHL formulations (oral or nebulized) for the treatment of allergenic disorders.
View Article and Find Full Text PDFEcthyma amidst the global monkeypox outbreak: A key differential? -A case series.
IDCases
December 2024
Department of Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
Background: Ecthyma is a deeper form of impetigo involving the epidermis and dermis causing ulcerative plaques. Pathogens commonly responsible for the disease (group A beta-hemolytic streptococcus and Staphylococcus aureus) typically afflicts children, presenting during early stages with skin lesions that can closely resemble other vesicular and ulcerative dermatoses, such as those observed in mpox infection. The ongoing global outbreak of monkeypox has escalated the urgency for clinicians to accurately differentiate between these conditions due to their overlapping dermatological manifestations.
View Article and Find Full Text PDFBiologics and small molecules: the re-evolution in the treatment of atopic dermatitis in children and adolescents. Current state of the art and future perspectives.
Expert Rev Clin Immunol
January 2025
Department of Woman, Child and of General and Specialized Surgery, University of Campania 'Luigi Vanvitelli', Napoli, Italy.
Introduction: In recent years, the understanding of atopic dermatitis (AD) pathogenetic mechanisms has expanded and now it is recognized that Th2 immune axis dysregulation is pivotal to AD pathogenesis. The advent of biological drugs and small molecules have marked a revolution in the treatment of AD. Dupilumab, targeting IL-4 and IL-13, has been the first to demonstrate efficacy in treating moderate to severe AD by modulating type-2 inflammation pathways.
View Article and Find Full Text PDFAssociations of Atopic Dermatitis in Late Adolescence with Occupation, Mental Health, Income from Work and Marital Status: A National Longitudinal Study.
Acta Derm Venereol
January 2025
School of Medical Sciences, Örebro University, Örebro, Sweden; Department of Occupational and Environmental Dermatology, Lund University, Malmö, Sweden.
The main aim of this study was to evaluate longitudinal associations between atopic dermatitis (AD) in late adolescence and occupational socioeconomic group, labour market participation, income from work, and marital status later in adult life. Using Swedish population-based registry data a total of 205,394 men were included, born between 1952 and 1956 in Sweden and who underwent military conscription examination including assessment of atopic dermatitis (AD) and AD severity. The associations between AD and AD severity in late adolescence and labour market participation, income from work, marital status, and medication for anxiety and depression later in adult life were examined.
View Article and Find Full Text PDFThe association of HLA-DRB1 allele group but not HLA-B or ERAP1-rs7063 gene polymorphisms with atopic dermatitis.
Hum Immunol
January 2025
Laboratory of Immunogenetics and Tissue Immunology, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.
Atopic dermatitis (AD) is one of the most common dermatoses. According to current data 2.6 % of the world's population suffer from AD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!